

September 19, 2023

BSE Limited 1st Floor, P J Towers, Dalal Street, <u>Mumbai-400001</u>

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), <u>Mumbai-400051</u> Code: Zyduslife

Re.: <u>Press Release</u>

Dear Sir / Madam,

Please find enclosed a copy of press release dated September 19, 2023 titled **"Zydus receives EIR for the formulation manufacturing facility at SEZ 2, Ahmedabad**".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully, For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above



Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Zydus receives EIR for the formulation manufacturing facility at SEZ 2, Ahmedabad

• The inspection had concluded with NIL observations

Ahmedabad, India, September 19, 2023

We wish to inform that the company has received the EIR report from the USFDA for the inspection conducted at the formulation manufacturing facility named 'SEZ 2' located at Pharmez, Ahmedabad from 3rd to 7th July, 2023. This was a Pre-Approval Inspection (PAI) and had concluded with NIL observations.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

About Zydus

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 24000 people worldwide and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com.



For further information please contact : The Corporate Communications Department

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 | website : www.zyduslife.com CIN : L24230GJ1995PLC025878